Riociguat for Sarcoidosis-Associated Pulmonary Hypertension

Autor: Rohit Gupta, Steven D. Nathan, Oksana A. Shlobin, Jeffrey I. Stewart, Robert P. Baughman, Franck Rahaghi, Elyse E. Lower, Joyce Zeigler, Peter J. Engel

Publikováno v: Chest. 161:448-457

Background Riociguat is effective in delaying the time to clinical worsening (TCW) in patients with groups 1 and 4 pulmonary hypertension. Research Question Is riociguat more effective than placebo in prolonging TCW in sarcoidosis-associated pulmonar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cddc0e4b1aa36279a2ba1f66f1eeafdf
https://doi.org/10.1016/j.chest.2021.07.2162

Clinical features of sarcoidosis associated pulmonary hypertension: Results of a multi-national registry

Autor: Robert P. Baughman, Steven D. Nathan, Joseph Barney, Francis Cordova, Daniel A. Culver, Vasilis Kouranos, Joseph G Cal, Elyse E. Lower, Mary Beth Scholand, JoAnne Baran, Marlies S. Wijsenbeek, Oksana A. Shlobin, Sivagini Ganesh, Surinder S. Birring, Athol U. Wells, Peter J. Engel, Eva M. Carmona, Esam H. Alhamad, Lanier O'Hare

Publikováno v: Respiratory Medicine, 139, 72-78. W.B. Saunders
Baughman, R P, Shlobin, O A, Wells, A U, Alhamad, E H, Culver, D A, Barney, J, Cordova, F C, Carmona, E M, Scholand, M B, Wijsenbeek, M, Ganesh, S, Birring, S S, Kouranos, V, O'Hare, L, Baran, J M, Cal, J G, Lower, E E, Engel, P J & Nathan, S D 2018, ' Clinical features of sarcoidosis associated pulmonary hypertension : Results of a multi-national registry ', Respiratory Medicine, pp. 72-78 . https://doi.org/10.1016/j.rmed.2018.04.015

Background Pulmonary hypertension (PH) is a significant cause of morbidity and mortality in sarcoidosis. We established a multi-national registry of sarcoidosis associated PH (SAPH) patients. Methods Sarcoidosis patients with PH confirmed by right he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cc564636b35763bf8aad4a30ab54b2b
https://hdl.handle.net/1765/106407

Pulmonary Hypertension in Sarcoidosis

Autor: Robert P. Baughman, Peter J. Engel, Steven D. Nathan

Publikováno v: Clinics in Chest Medicine. 36:703-714

Pulmonary hypertension is a complication of sarcoidosis leading to dyspnea and associated with increased morbidity and mortality. Sarcoidosis-associated pulmonary hypertension (SAPH) can be due to several factors, including vascular involvement by th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4715628511dcb37d6f71450a0bcd8d7e
https://doi.org/10.1016/j.ccm.2015.08.011

Invasive Techniques for Diagnosis of PH

Autor: Peter J. Engel

Publikováno v: Pulmonary Hypertension and Interstitial Lung Disease ISBN: 9783319499161

During the past two decades, there has been significant progress in the diagnosis and treatment of pulmonary hypertension. As a result of several World Symposia, the definition and classification of PH has been revised and refined. PH is now consider

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1f2479ba5880ed6b43650115a1b72ef4
https://doi.org/10.1007/978-3-319-49918-5_2

Survival in Sarcoidosis-Associated Pulmonary Hypertension

Autor: Lisa Taylor, Robert P. Baughman, Elyse E. Lower, Peter J. Engel

Publikováno v: Chest. 138:1078-1085

Objective: Pulmonary hypertension (PH) has been associated with increased mortality in patients with advanced pulmonary sarcoidosis. Sarcoidosis-associated PH may be the result of left ventricular dysfunction (LVD) or isolated pulmonary vasculature a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c1bff163147bd7de84ce1d77ceba57e9
https://doi.org/10.1378/chest.09-2002